CTOs on the Move

QuVa Pharma, Inc

www.quvapharma.com

 
QuVa Pharma, Inc. is a newly-formed national platform for sterile compounding pharmacy services led by two experienced industry executives that has received a majority equity commitment from Bain Capital Private Equity to support the company’s creation and expansion plans. As part of its formation, QuVa Pharma has acquired the assets of the compounding services division of a company leader in the field of parenteral and management services, including its state-of-the-art 503B manufacturing facility in Sugar Land, Texas.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.quvapharma.com
  • 1075 W. Park One Drive Suite 100
    Sugar Land, TX USA 77478
  • Phone: 888.339.0874

Executives

Name Title Contact Details

Funding

QuVa Pharma, Inc raised $41M on 07/26/2018
QuVa Pharma, Inc raised $275M on 05/06/2021

Similar Companies

Central Connecticut Coast YMCA

Since 1859 the Central Connecticut Coast Y branches have served as community centers in the heart of the twenty-five towns we serve. Much of the Central Connecticut Coast Y’s work is supported by membership dues, program fees and grants, but central to...

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.

Roo-Lan Healthcare Center

Roo-Lan Healthcare Center is a Lacey, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allied Health Care Services

We are committed to the people of our community, to help them overcome challenges and reach their greatest potential by providing quality care, people-oriented services and comfort.

GoGoMeds

GoGoMeds is a cloud-based pharmacy that utilizes technology to provide customers with affordable quality medications delivered to their door.